Industri Jamu dan Farmasi Sido Muncul clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.
Pain ManagementWomen's HealthAllergyNutraceuticalAlternative MedicineWellness and RecoveryHealth CareHealth DiagnosticsMedical
Description
PT Industri Jamu dan Farmasi Sido Muncul Tbk is a prominent player in the herbal medicine and pharmaceutical industry in Indonesia.
The company specializes in the production and distribution of traditional herbal products, dietary supplements, and p…
Analysis
Quality compounder
PT Industri Jamu dan Farmasi Sido Muncul Tbk earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.
On valuation, the picture is attractive. The owner-earnings multiple stands at 8.3×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around -6% a year, against analyst forecasts of 2%. The price, in other words, assumes less than the experts do.
Growth is moderate; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Jan 2023100
56
2023202420252026
All-time high
100
Jan 2025
All-time low
56
Jun 2026
Average rank
79
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
50
49
53
26
Price/Earnings
83
77
84
63
Price/Book
44
46
48
34
Dividend Yield
99
94
96
92
Value (overall)
86
77
79
63
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.